AIチャット

Aclarion, Inc.

ACONW · NasdaqCM · USD

0.02 -0.01 (-33.33%)

終値時点: Oct 21, 2026, 3:30 PM EDT

出来高
7.93K

Aclarion, Inc.(ACONW)の株価・分析・データ

間隔:1D
ローソク足とシグナルを読み込み中…

本源的価値

バリュエーションモデルは Pro の機能です。サインインまたはアップグレードすると分析全体を表示できます。

プランを見る →

アナリスト予想

株価予想 →

アナリスト予測は利用できません

12か月目標株価 · アナリストn/a人

アナリストのコンセンサス: n/a

無料の概要を表示しています

無料アカウントを作成して、この銘柄に関するさらに詳しいリサーチをご覧ください。

業績

財務情報を見る →

読み込み中...

最新決算

実績予想との差前年比
売上高—n/an/a
EPS(TTM)—n/an/a

次回決算

決算の詳細を見る →

事業指標

買気配
n/a
純利益(TTM)
-9.2M
1.21
-6.58
n/a
n/a
PBR(TTM)
0.00
PSR(TTM)
n/a
決算発表日
n/a
売気配
n/a
出来高
7,928
平均出来高(20日)
n/a
始値
0.05
前日終値
0.03
当日レンジ
0.02 - 0.02
52週レンジ
0.02 - 0.02
配当
n/a
権利落ち日
n/a

Aclarion, Inc.について

企業情報を見る →
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado. ·

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

業種
セクター
IPO日 Jul 17, 2026
従業員数 10
上場取引所 NasdaqCM
ティッカー ACONW
ウェブサイト https://www.aclarion.com